Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 4 150 mg product-specific bioequivalence guidance

  • Email
  • Help
Current version

Adopted guideline

Reference numberEMA/CHMP/805498/2016
Published22/12/2016
Effective from01/12/2018
KeywordsBioequivalence, generics, dabigatran etexilate
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of dabigatran etexilate.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration


Document history

First version
Current version

Adopted guideline
 

 

Overview of comments
 

Draft guideline

Published: 26/06/2018
Effective from: 01/12/2018

 

Published: 26/06/2018

 

Published: 22/12/2016

Related content


How helpful is this page?

Average rating:

 Based on 23 ratings

Add your rating:

See all ratings
5 ratings
4 ratings
4 ratings
4 ratings
6 ratings
    

Tell us more